Compare CNVS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNVS | SCYX |
|---|---|---|
| Founded | 2000 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.6M | 51.4M |
| IPO Year | 2016 | 2014 |
| Metric | CNVS | SCYX |
|---|---|---|
| Price | $2.25 | $4.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.00 | $3.00 |
| AVG Volume (30 Days) | ★ 132.6K | 77.9K |
| Earning Date | 02-17-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,733,000.00 | $257,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $84.42 | $608.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.77 | $0.57 |
| 52 Week High | $3.55 | $6.09 |
| Indicator | CNVS | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 32.80 | 46.66 |
| Support Level | $1.93 | $4.65 |
| Resistance Level | $2.26 | $5.10 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 4.35 | 1.68 |
Cineverse Corp is a technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, and audio podcasts, Podcast, Media services, and Other non-recurring. Its brands include Hallmark, ITV, Nelvana, ZDF, Konami, NFL, and Highlander.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.